|
|||||
|
|
Preventing tomorrow's sudden cardiac death today: part II: Translating sudden cardiac death risk assessment strategies into practice and policy |
|
| Authors: | Sanders Gillian D,Al-Khatib Sana M,Berliner Elise,Bigger J Thomas,Buxton Alfred E,Califf Robert M,Carlson Mark,Curtis Anne B,Curtis Jeptha P,Domanski Michael,Fain Eric,Gersh Bernard J,Gold Michael R,Goldberger Jeffrey,Haghighi-Mood Ali,Hammill Stephen C,Harder Joel,Healey Jeffrey,Hlatky Mark A,Hohnloser Stefan H,Lee Kerry L,Mark Daniel B,Mitchell Brent,Phurrough Steve,Prystowsky Eric,Smith Joseph M,Stockbridge Norman,Temple Robert Expert panel participating in a Duke Center for the Prevention of Sudden Cardiac Death-sponsored conference |
| Affiliation: | a Duke Clinical Research Institute, Duke Medical Center, Durham NC b Agency for Healthcare Research and Quality, Rockville, MD c Columbia University, New York, NY d Rhode Island Hospital, Providence, RI e St Jude Medical, Sunnyvale, CA f University of South Florida, Tampa, FL g Yale University School of Medicine, New Haven, CT h National Heart Blood and Lung Institute, National Institutes of Health, Bethesda, MD i Mayo Clinic, Rochester, NY j Medical University of South Carolina, Charleston, SC k Northwestern University Medical School, Chicago, IL l Cambridge Heart Inc, Bedford, MA m Heart Rhythm Society, Washington, DC n McMaster University, Hamilton General Hospital, Hamilton, Ontario, Canada o Stanford School of Medicine, Stanford, CA p JW Goethe University, Frankfurt, Germany q Libin Cardiovascular Institute of Alberta, Calgary, Alberta, Canada r Centers for Medicare and Medicaid Services, Baltimore, MD s St Vincent's Hospital, Indianapolis, IN t Boston Scientific, Inc, St Paul, MN u Food and Drug Administration, Silver Spring, MD |
| Abstract: | Although current evidence supporting a more precise strategy for identifying patients at highest risk for sudden cardiac death (SCD) is sparse, strategies for translating existing and future evidence into clinical practice and policy are needed today. A great many unanswered questions exist. Examples include the following: At what level of risk for SCD should we pursue further testing or therapy? How should clinical strategies ethically and economically balance alternative outcomes? How can we best translate optimal strategies into clinical practice so as to prevent tomorrow's SCDs? On July 20 and 21, 2006, a group of individuals with expertise in clinical cardiovascular medicine, biostatistics, economics, and health policy was joined by government (Food and Drug Administration; Centers for Medicare and Medicaid Services; National Heart, Lung, and Blood Institute; Agency for Healthcare Research and Quality), professional societies (Heart Rhythm Society), and industry to discuss strategies for risk assessment and prevention of SCD. The meeting was organized by the Duke Center for the Prevention of Sudden Cardiac Death and the Duke Clinical Research Institute. This article, the second of 2 documents, summarizes the policy discussions of that meeting, discusses an analytic framework for evaluating the risks and benefits associated with SCD prevention and risk stratification, and addresses the translation of SCD risk assessment strategies into practice and policy. |
| Keywords: | |
| 本文献已被 ScienceDirect PubMed 等数据库收录！ | |